Triple artemisinin-based combination therapies for malaria: a timely solution to counter antimalarial drug resistance

Affiliations

¹ Department of Epidemiology and Biostatistics, Institute for Global Health Sciences, University of California, San Francisco, CA, USA. Electronic address: ingrid.chen@ucsf.edu.
² Department of Epidemiology and Biostatistics, Institute for Global Health Sciences, and Department of Pediatrics, University of California, San Francisco, CA, USA.

Comment

Ingrid Chen et al. Lancet Infect Dis. 2022 Jun.

. 2022 Jun;22(6):751-753.

doi: 10.1016/S1473-3099(21)00748-9. Epub 2022 Mar 8.

¹ Department of Epidemiology and Biostatistics, Institute for Global Health Sciences, University of California, San Francisco, CA, USA. Electronic address: ingrid.chen@ucsf.edu.
² Department of Epidemiology and Biostatistics, Institute for Global Health Sciences, and Department of Pediatrics, University of California, San Francisco, CA, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.
Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, Thuong NTH, van der Pluijm RW, Dung NTP, Sokha M, Van Luong V, Long LT, Sovann Y, Duanguppama J, Waithira N, Hoglund RM, Chotsiri P, Chau NH, Ruecker A, Amaratunga C, Dhorda M, Miotto O, Maude RJ, Rekol H, Chotivanich K, Tarning J, von Seidlein L, Imwong M, Mukaka M, Day NPJ, Hien TT, White NJ, Dondorp AM. Peto TJ, et al. Lancet Infect Dis. 2022 Jun;22(6):867-878. doi: 10.1016/S1473-3099(21)00692-7. Epub 2022 Mar 8. Lancet Infect Dis. 2022. PMID: 35276064 Free PMC article. Clinical Trial.